While a large body of evidence supports the idea that DRP1-mediated mitochondrial fission is pro-tumorigenic in nature [51–54], including in breast cancer [55], our findings clearly indicate that EPHB6-positive tumour cells should be more susceptible to DR5-activating therapeutic approaches. This evidence concerns the gene EPHB6 and breast cancer.